A taper is arithmetic. Treating the reason is not.

Opioid tapering carries measurable risk: in a cohort of 113,618 adults on long-term opioids, tapering was associated with more overdose, withdrawal and mental health crisis events, and faster reductions raised both. The lever that is not the dose is treating the pain generator, so the dose falls because the input fell.

A dose reduction is not a treatment. It is a change to one number, and whether it helps or harms depends entirely on what else was changed at the same time.

Is opioid tapering dangerous?

This site’s tapering principles hold that a taper and a withdrawal differ by four things: agreement, rate, monitoring, and a way back. The opioid literature is where that claim has been most expensively tested.

In a retrospective cohort of 113,618 adults on stable long-term therapy at 50 morphine milligram equivalents a day or more, tapering was associated with an adjusted 9.3 overdose or withdrawal events per 100 person-years against 5.5 in non-tapered periods (aIRR 1.68), and 7.6 mental health crisis events against 3.3 (aIRR 2.28). Rate mattered independently: each 10% increase in maximum monthly dose-reduction velocity carried an aIRR of 1.09 for overdose and 1.18 for mental health crisis.

A companion analysis followed the same population further out and found the elevated rates persisting into the second year after taper initiation — 1.57 for overdose or withdrawal and 1.52 for mental health crisis, comparing post-induction with pre-taper periods.

Both are observational, and the authors say so. Sicker patients get tapered, and that confounding cannot be fully removed. But the direction is consistent, the dose-response on velocity is what you would predict if the mechanism were real, and nothing in the deprescribing literature suggests the opposite.

What lowers an opioid dose besides a taper?

The policy response of the last fifteen years treated quantity as the only available variable. It is not the only one, and the alternative is not a slower version of the same maneuver.

Sustained opioid exposure produces tolerance, in which the drug still works but more is required, and can produce opioid-induced hyperalgesia, in which the nervous system is recalibrated toward pain and additional drug makes it worse. The mechanisms proposed for the latter center on the central glutamatergic system and NMDA receptor activation, spinal dynorphin, and descending facilitation. Where hyperalgesia is operating, one review states plainly that further opioid prescribing is largely futile.

The clinically useful consequence is the one that gets least attention: a 2019 review notes that interventional techniques which reduce pain input can permit a dose decrease and, in doing so, revert the mechanisms producing tolerance and hyperalgesia. The dose falls because the input fell. That is a different event from a taper, and it is the event the four conditions above are trying to approximate when no such option exists.

Can treating the pain source get patients off opioids?

On International Overdose Awareness Day in August 2026, Dr. Gurpreet Singh Padda — who directs the clinical positions this site is built on — published the opioid figures from his interventional pain practice.

• Average arrival: more than 90 MME per day, after more than two and a half years in pain.
• 21% completely off opioid pain medication within 90 days of active interventional treatment; 34% within one year.
• Of those not fully weaned, the large majority held below 30 MME per day.

These are practice-reported figures from a single population, not trial outcomes, and individual results vary. There is no control arm, no independent adjudication and no randomization; they cannot be read as evidence that this approach outperforms another. What they do illustrate is the mechanism — a population in which the dose fell as a downstream consequence of treating pain generators, rather than as the primary intervention. Reported by AP News; full release.

For contrast on what dose reduction achieves without that: a randomized trial of a group-based self-management program in 608 primary-care patients on strong opioids produced a large increase in discontinuation at 12 months (29% versus 7%) and no improvement in pain interference. Getting people off the drug and improving their lives are two different endpoints, and they can move independently.

Is opioid tapering different for older adults?

The patients this site concerns are rarely on opioids alone. They are on opioids inside a list, frequently with sedatives, and the interaction risk is what turns a modest dose into a fall or a delirium. That argues for reduction. The tapering data argue for reducing carefully, with monitoring and a way back — and for asking, before starting, what is generating the pain and whether anything can be done about it directly. See opioids in older adults and the deprescribing framework.

The summary a prescriber can act on: a taper is arithmetic, and arithmetic performed on a patient whose pain generator is untreated is the scenario the cohort studies were measuring.

Frequently asked questions

Do opioids need to be tapered instead of stopped all at once?

Yes. Opioids cause a withdrawal syndrome when they are stopped abruptly, so they have to be reduced gradually under a prescriber’s supervision. Never stop or change a prescribed opioid on your own. A taper done well rests on four things: your agreement, a sensible rate, monitoring along the way, and a way back if the reduction goes badly.

Is it dangerous to taper opioids too fast?

Speed matters. In a study of 113,618 adults on long-term opioids, tapering was linked to more overdose, withdrawal and mental health crisis events, and each 10% increase in how fast the monthly dose dropped raised those risks further. The higher rates lasted into the second year. The study was observational, but the pattern points the same way throughout.

Why can long-term opioids make pain worse?

Two things happen with sustained use. Tolerance means the drug still works, but more is needed. Opioid-induced hyperalgesia goes further: the nervous system is reset toward pain, and more of the drug makes pain worse. Where hyperalgesia is at work, one review states that prescribing more opioids is largely futile. Lowering the pain input is what lets that process reverse.

Does getting off opioids make pain better?

Not on its own. In a randomized trial of 608 primary-care patients on strong opioids, a group self-management program raised the share who stopped opioids at 12 months from 7% to 29%, yet pain interference did not improve. Coming off the drug and feeling better are separate goals. The answer here is to treat what is generating the pain, so the dose falls because the pain input fell.

How many patients come off opioids when the pain source is treated?

In Dr. Padda’s interventional pain practice, arriving patients average more than 90 MME per day after more than two and a half years in pain. With active interventional treatment, 21% are completely off opioid pain medication within 90 days and 34% within one year. These are practice-reported figures from his own population, not trial outcomes, and individual results vary.

References

1. Agnoli A, Xing G, Tancredi DJ, Magnan E, Jerant A, Fenton JJ. Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids. JAMA. 2021;326(5):411–419. PMID 34342618 · DOI 10.1001/jama.2021.11013.
2. Fenton JJ, Magnan E, Tseregounis IE, Xing G, Agnoli AL, Tancredi DJ. Long-term risk of overdose or mental health crisis after opioid dose tapering. JAMA Network Open. 2022;5(6):e2216726. PMID 35696163 · DOI 10.1001/jamanetworkopen.2022.16726.
3. Mercadante S, Arcuri E, Santoni A. Opioid-induced tolerance and hyperalgesia. CNS Drugs. 2019;33(10):943–955. PMID 31578704 · DOI 10.1007/s40263-019-00660-0.
4. Colvin LA, Bull F, Hales TG. Perioperative opioid analgesia — when is enough too much? A review of opioid-induced tolerance and hyperalgesia. The Lancet. 2019;393(10180):1558–1568. PMID 30983591 · DOI 10.1016/S0140-6736(19)30430-1.
5. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145–161. PMID 21412369.
6. Sandhu HK, Booth K, Furlan AD, et al. Reducing opioid use for chronic pain with a group-based intervention: a randomized clinical trial. JAMA. 2023;329(20):1745–1756. PMID 37219554 · DOI 10.1001/jama.2023.6454.

Bibliographic records in this note were retrieved from PubMed. Every reference links to its PubMed record and DOI.

Written and medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, founder and medical director of DWARAA. Last reviewed August 31, 2026. This page is educational. DWARAA does not prescribe, deprescribe, diagnose or treat.